Literature DB >> 2197840

Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.

R J Tickman1, C Cohen, V A Varma, P S Fekete, P B DeRose.   

Abstract

The usefulness of an immunoperoxidase battery to distinguish carcinomatous from benign effusions was examined. Cell block sections from 90 previously diagnosed effusions were stained with antibodies to Leu-M1, B72.3, epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA) and vimentin. The 90 cases comprised 69 carcinomas (23 mammary, 16 ovarian, 10 pulmonary, 7 gastrointestinal [GI] and 13 others), 2 malignant mesotheliomas and 19 cases with reactive mesothelial cells only. EMA and vimentin were the most useful markers for distinguishing carcinoma cells from reactive mesothelial cells. EMA reacted with 86% of the carcinomas while vimentin reacted with 90% of the reactive cases. Leu-M1, B72.3 and CEA, although generally less sensitive than EMA, were also helpful in this regard. Additionally, the use of Leu-M1 and CEA together may help to distinguish pulmonary from GI carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197840

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

Review 1.  Update on special techniques in routine cytopathology.

Authors:  I D Buley
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

2.  Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion.

Authors:  Chang Gok Woo; Seung-Myoung Son; Hye-Suk Han; Ki Hyeong Lee; Kang-Hyeon Choe; Jin Young An; Ki Man Lee; Young Hyun Lim; Ho-Chang Lee; Ok-Jun Lee
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Development of a sensitive, specific reverse transcriptase polymerase chain reaction-based assay for epithelial tumour cells in effusions.

Authors:  M Sakaguchi; A K Virmani; R Ashfaq; T E Rogers; A Rathi; Y Liu; D Kodagoda; H T Cunningham; A F Gazdar
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.